Thank you for keeping it real Mr D.Facts Rule!

This one is a much better explanation imo.
Insider Selling Isn't Always A Bad Sign

By Glenn Curtis on September 20, 2013

A A A

Filed Under: Insider Trading, Laws & Regulation, SEC



Insiders at public companies essentially have two options for buying and/or selling their companies' stock. The first is to conduct the transactions in the open market. That is, they can buy or sell securities through a broker just like any other retail investor. The second option is to conduct the transaction on a systematic basis through what is called a 10b5-1 plan. This Securities and Exchange Commission (SEC) rule permits a systematic form of insider trading that is not only legal, but can also be beneficial for both the insiders (and their companies) and individual investors. Read on to learn more.

What is a 10b5-1 plan?
Rule 10b5 is one of the most important acts put forth by the SEC. This rule makes it unlawful to defraud, mislead or operate in any fraudulent manner in transactions of securities on national exchanges.

This rule was also enacted to prohibit the purchase or sale of a security on the basis of non-public information. Any trade made with material non-public information, or insider information, is deemed as insider trading and is illegal under Rule 10b5.

In 2000, the SEC made an administrative ruling, known as 10b5-1, or 10b5-1 (c), which allows for a defense against the insider trading rule as long as the individual can determine that no non-material insider information was used as the basis for the trade.

This ruling created a situation where insiders could create a trading plan in advance of a trade if they set a specific date or price at which to effect a transaction (either a purchase or a sale). When that event transpired, it triggered the trade. These trading plans are known as 10b5-1 plans.

For example, executives may want to purchase shares throughout the calendar year. To do so, they (under the plan) purchase a fixed number of shares at specified dates, such as the first trading day of the month. The transaction is automatic. The insider will be safe even if he or she has insider information at the time of the sale, as long as the plan was set up when no material non-public information was known.

Conversely, if an insider wants to diversify his or her holdings but doesn't want to sell a large portion of stock at any one time for fear that it might send the wrong message to the investment community, the individual may set up a plan that liquidates 1,000 shares per month over the next year. Again, the trades are automatic and take place at a set point in time.

Benefits for Insiders
There are several benefits of 10b5-1s for both insiders and individual investors:

A Better Appearance
Because a 10b5-1 is a pre-set systematic method of accumulating and/or disposing of shares, the possession of insider information becomes essentially irrelevant. By definition, this will help stem accusations of insider trading and/or front running after a trade is consummated. In short, for executives at high profile companies that are frequently the target of shareholder suits and almost always subject to scrutiny from the investment community, this system can be invaluable.

Windows and Blackout Periods Don't Matter
Many - if not most - companies have established trading windows, or time periods when an individual executive may conduct a transaction in the stock. Many companies have also established blackout periods where, during a certain time period, absolutely no transactions in the company stock may be effectuated.





Say hi to 360 Checking & bye to fees. Open & snag a $50 bonus.
However, a 10b5-1 renders both of these strategies moot. That's because the trades are systematic and take place regardless of whether the individual has inside information or the company is about to report good or bad news.

Eliminates the Need to Read Into Insider Data
When an insider buys or sells stock on the open market, the law states that the company/insider must make the trade details public. When this data is reported to the SEC, major news wires and/or market data providers will then disseminate it widely to their readership or client base (particularly if the transaction was effectuated by an individual at a well-known company). Furthermore, in many instances the data may also be interpreted and used by journalists in their articles.

Unfortunately, when data is released in this manner it is sometimes wrongly interpreted. In other words, when an insider sells his or her stock, some may interpret the transaction as though he or she no longer stands behind the company, when in fact the transaction may represent only a small portion of the individual's assets.

Conversely, small insider purchases are sometimes construed as an indicator that the current price offers a terrific buying opportunity, when in fact the insider intends to make purchases in the future at numerous prices.

The Benefits for Investors
Limits Incorrect Interpretations and Makes Intentions Known
Insider data is sometimes wrongly interpreted by individual investors and/or large institutional shareholders, which can lead to mass selling or mass buying. However, when an executive consistently buys or sells shares each month (or quarter, or at some other pre-established period), the investment community becomes aware of the plan and will not typically react with such blind emotion.

Also, when an insider sells stock on the open market, investors typically look just at the transaction. They tend to ignore other characteristics of the trade and/or evidence of why the insider may have initiated the purchase or sale.

For example, if an insider sells 5,000 shares of XYZ stock, the only thing that most investors will hear or see is the date the stock was sold, who sold it and at what price. But they won't know, for example, whether the sale of 5,000 shares makes up only a tiny portion of what the executive continues to hold and believe in.

When a systematic plan is in place, investors will be able to see the insider's intentions more clearly. For example, when certain insiders liquidate shares at consistent points throughout the year, investors are more apt to be aware of and understand that an insider is simply diversifying his or her holdings, and that the remaining sizable position in the stock implies confidence in the company.

Investors Know What to Expect and When to Expect It
Part of the problem with insider data reporting is the time it takes for such information to reach the average investor. While the SEC mandates that Form 4 (filings that must be made when changes in ownership occur) must be filed within two business days of a trade, it sometimes takes a week or more for that data to circulate to the average shareholder through news services or some other data provider.

Data/trade information may also come to investors at an inopportune time - like on a Friday afternoon when many traders like to go home "flat" (or without any long positions). When this happens, it could exacerbate the normal selling. That said, when a systematic plan is used investors know, or should expect to see, sales (or purchases) at given points in time. This is comforting to many shareholders.

Bottom Line
Systematic investment plans are much more beneficial for both insiders and individual investors than transactions effectuated on the open market. A 10b5-1 plan allows executives to diversify their holdings without creating a stir in the investment community, and allows investors to keep an eye on executives' sales of shares.

I am sure I will get flack for this post, but I look at all info good or bad.This is interesting and in no way am I saying any of this is happening especialy with Apri the sells are far apart.Its just smart in my opinion.The price will still go up next week to show that the fear mongers will be wrong again.The SEC Is Eyeing Insider Stock Sales

March 18, 2007






Are executives using inside information to boost returns when they sell stock through automatic trading plans? That was the conclusion reached in the first academic study of such plans, as reported by BusinessWeek on Dec. 18. Troubled by those results, now the Securities & Exchange Commission is looking more closely at such trades and whether the rules governing them need to be tightened, BusinessWeek has learned. The way the plans are being used "isn't how they were supposed to work," said a source familiar with the agency's views.

The move comes as broader concerns have grown regarding prearranged trading plans, known as 10b5-1 plans for the 2000 rule that created them. Some investors have begun to track them closely. And revelations about two founders of New Century Financial Corp. (NEW), the mortgage firm whose stock collapsed after an announcement it would restate 2006 earnings, could raise new questions about such sales: Some months before, the pair sold shares worth $26 million through trading plans.

The SEC's goal in creating automatic trading plans was to allow executives to sell shares without triggering insider trading charges. To gain that legal "safe harbor," however, executives must meet certain conditions. They must set up a trading plan when they don't know of any significant nonpublic information, lay out the dates or prices at which trades will be made in advance, and give up control of the trades to a broker.

Those limited rules allow executives more maneuvering room to time sales than is generally understood. According to the study by Alan D. Jagolinzer, an assistant professor at the Stanford University Graduate School of Business, executives selling shares through 10b5-1 plans do substantially better than would be expected if trading were truly automatic. In a study of roughly 117,000 trades made by 3,426 executives at 1,241 companies, trades made inside plans beat the market by 6% over six months, while those at the same firms who traded outside of plans only topped it by 1.9%.

More often than not, sales made through plans by insiders occur ahead of a stock drop. The rules also allow executives to end plans before they've been fully executed, set up multiple short-term plans, and begin selling immediately after adopting a plan. "I wouldn't have thought the plans allowed this much flexibility," says a source familiar with Jagolinzer's study. "His work clearly raises questions about the trading strategies people are using and if they are going well beyond what was envisioned."

The report has prompted the SEC to undertake a more detailed analysis of 10b5-1 plans. If the commission eventually concludes that problems exist, it could change how it evaluates cases for potential enforcement action; it could also propose tightening the rules governing such trades. Greater public disclosure of an executive's trading strategy, or of the dates when a plan is started or ended, might be required. H. Nejat Seyhun, a finance professor at the University of Michigan's Ross School of Business, also thinks stiffer trading controls are needed: Sales might be banned until six months after a plan is put into effect, for example, or an executive who ends a plan prematurely or makes other changes might lose the safe harbor protection.

The SEC's enforcement officials are also keeping a close eye on 10b5-1 trades, although the agency has yet to challenge a plan by bringing an insider trading case against an executive with one in place. And growing questions about the plans could be fueled by the trades made at New Century. Its shares have plummeted to around $5 in the wake of a Mar. 2 announcement that federal prosecutors are probing its accounting, as well as looking at trading in its securities following New Century's warning in early February that it would have to restate 2006 earnings. Between August and November of last year, two founders, Robert Cole and Edward Gotschall, sold roughly 650,000 shares, at prices averaging just below $40, through automatic trading plans. The company declined to comment. Prosecutors and the SEC would not comment on whether those trades are among those being probed.

Some investors, too, appear to be paying closer attention to such plans. Gradient Analytics Inc., an independent research firm, warned clients last year to steer clear of companies with overly aggressive automatic trading plans. Now it regularly analyzes such plans in recommending stocks to buy or sell. "Plans being instituted are becoming more creative," says Carr Bettis, a former finance professor who co-founded Gradient. "They've been around long enough for people to find ways to use them to their advantage."

By Jane Sasseen

Mr .D is right,although the spin doctors will im sure have a field day with the info.An insider automatic stock sale is a plan (often called a 10b-5 plan) that provides that an insider will trade shares automatically in amounts and on dates set forth in the plan. It could be "sell 1,000 shares every Friday" or it could be very complicated (e.g. "sell 1,000 shares if the price hits $10 and the trading volume is at least 100,000 shares"). The reason for it is because insiders often can't sell because they have insider information. Trading with inside information is illegal. But by having an automatic plan, the insider is not trading on inside information (the trade is automatic and will happen regardless of any inside knowledge).
Source(s):
http://www.klehr.com/Articles/bs_kl1202.…

You got it Mr. D And I think he was already there, I just drove him further. GOOD LUCK!

Another bid at $2.32 just in case.NO FEAR HERE!

I bought more at $2.48 my average price per share is now $3.28 a share. Kids need a new house. LOL!

Love this chart = http://www.stockta.com/cgi-bin/analysis.pl?symb=APRI&cobrand=&mode=stock

Yep = http://www.investing.com/equities/apricus-biosciences-candlestick

http://www.stockta.com/cgi-bin/analysis.pl?symb=APRI&cobrand=&mode=stock

Thanks Aprilov

Merry Xmas and still short market day to go. Be Safe!

https://research.tradeking.com/research/quotes/stock-news/story.asp?key=100-357x7943-1&lastPage=price-quote&lastSymbol=APRI&mcsymbol=APRI

I know this is old, but it says patent good thru 2019.I know this could be nothing but I never heard of Femprox Japan patent.Sorry for posting if a no news post.I am searching constantly for news. http://www.businesswire.com/news/home/20101018006654/en/Apricus-Bio-Announces-Patent-Grant-Femprox%C2%AE-Japan#.UrcMDo2A21sfor Also http://www.fiercebiotech.com/press-releases/apricus-bio-announces-first-patent-grant-femprox-japan

Nice recap for the new people. SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Apricus' or the 'Company') (Nasdaq:APRI) (www.apricusbio.com), today provided a third quarter corporate update, including clinical, commercial and regulatory strategies for its topical on-demand product Vitaros(r) for erectile dysfunction (ED') and its product candidate Femprox(r) for female sexual interest/arousal disorder ('FSIAD').

'Since the beginning of 2013, we have focused on the successful execution of our corporate goals, including gaining European regulatory approval for Vitaros(r), licensing the un-partnered Vitaros(r) territories in Europe, obtaining regulatory feedback from the FDA on Femprox(r) and streamlining our business,' said Richard Pascoe, Chief Executive Officer of Apricus. 'We continue to make progress on each of these fronts, including obtaining an approval for Vitaros(r) in Europe through the Decentralized Procedure ('DCP'), advancing our partnering discussions to include licensing Vitaros(r) to Laboratoires Majorelle in France, Monaco and Africa, obtaining regulatory advice from the FDA on Femprox(r), strengthening our balance sheet, and completing the divestiture of all non-strategic assets. Looking forward, our top priorities are to secure additional Vitaros(r) partnerships and support our commercialization partners' launch preparations for Vitaros(r). We expect to announce one or more additional Vitaros(r) partnerships this quarter and anticipate the rollout of multiple Vitaros(r) launches across Europe in 2014.'

Mr. Pascoe continued: 'Regarding Femprox(r), we received clear regulatory guidance from the FDA in August 2013, and together with our Scientific Advisory Board, have drafted a clinical development plan for Femprox(r) in the U.S. Given the recent DCP approval of Vitaros(r) in Europe, and the fact that Femprox(r) contains a unique concentration of the same active ingredient and novel proprietary permeation enhancer as Vitaros(r), we believe there may be a streamlined path to approval in Europe for Femprox(r). Therefore, we have requested a meeting with the European regulatory authorities to confirm whether a more rapid development path for Femprox(r) is possible in Europe. We expect this meeting to occur in the first quarter of 2014. Additionally, we are awaiting the outcome of an approval decision by the FDA for a competitive female sexual dysfunction product that we believe will help us further refine the Femprox(r) development strategy. With a well-defined U.S. regulatory path in hand, and with expected near term visibility on two critical pieces of regulatory feedback, we believe that shareholder interest will best be served by advancing Femprox(r) into the clinic with a development partner which we intend to pursue in early 2014.'

Vitaros(r)

-- Launch Preparations Underway. Vitaros(r) was approved in Europe under the DCP
in June 2013. Since then, Apricus, or its commercialization partners, have
received five national phase approvals in Europe, including Germany,
Ireland, the Netherlands, Sweden and the United Kingdom ('UK'). Apricus
continues to work independently, as well as with its partners, to obtain
country-by-country national phase approvals in the remaining CMS
territories including France, Spain, Belgium, Italy and Luxembourg. The
Company's regulatory efforts, along with actions taken by its existing
European partners, are on track to obtain the remaining five European
approvals. The Company has received commercial product orders from its
commercialization partners and manufacturing activities have commenced for
both sample and commercial product to support the expected Vitaros(r) launch
in Europe. In addition, our existing partners in Europe continue to prepare
for an expected commercial launch in their respective territories in 2014.
-- Partnering Initiative Remains on Track. In June 2013, Apricus launched a
comprehensive partnering process with the goal of licensing Vitaros(r) in the
remaining un-partnered territories in Europe, and the Emerging Markets,
including, Russia, Turkey, Latin America and Africa. The Company's key
partnering objectives for Vitaros(r) are to maximize the total deal value for
the asset, expand existing Vitaros(r) partnerships wherever possible, and
select partners who have a strong clinical, regulatory and commercial
presence in the respective territory. In addition to today's announcement
that we entered into a partnership with Laboratoires Majorelle in France,
Monaco and Africa, Apricus has received and reviewed multiple bids for the
available territories, has narrowed the number of potential partners to a
select group, and is negotiating with multiple parties. The Company expects
to complete negotiations and announce one or more new Vitaros(r) partnerships
in the fourth quarter of 2013.
-- Room Temperature Device and Other Manufacturing Initiatives Progressing.
Apricus continues to make progress with its next-generation, room
temperature version of Vitaros(r). This new version is expected to have a
targeted shelf life of at least 24 months and will not require
refrigeration. The Company has contracted with an additional manufacturing
partner that will serve as a second source of global supply for Vitaros(r).
The Company expects this second manufacturing site, located in Canada, will
be ready to supply cold chain Vitaros(r) product to its commercialization
partners in the second half of 2014. The site will also serve as the
primary manufacturing site for the ongoing room temperature Vitaros(r)
development program. Apricus believes this next-generation, room
temperature version will be a key driver of Vitaros(r) market growth and
expansion in 2015 and beyond.

Femprox(r)

-- Integrating Guidance from U.S. and European Health Authorities. Apricus
completed an End-of-Phase II meeting with the U.S. Food and Drug
Administration ('FDA') in late August 2013. In written guidance received
from the FDA following the meeting, the Agency concurred that the proposed
indication of FSIAD can be pursued in both pre- and post-menopausal women,
but that efficacy in each group must be demonstrated separately. The FDA
also concurred with the Company's proposed dosage levels, clinical
endpoints of Satisfying Sexual Events (SSE) and the arousal domain of the
female sexual function index ('FSFI'), and certain other study design
details. The Agency guided that a future study of Femprox(r) should
incorporate endpoints that would be used to validate the arousal domain of
FSFI. In addition, the FDA also stated that no additional non-clinical
studies, other than a reproductive and developmental assessment, would be
required to support a New Drug Application ('NDA'). The Company recently
met with its Scientific Advisory Board and has developed a draft clinical
development program for Femprox(r) in the U.S.

The Company believes there may be a more streamlined path to approval in Europe for Femprox(r). Therefore, Apricus is seeking regulatory guidance for Femprox(r) from the European regulatory authorities and expects to meet to gain insight from the authorities in the first quarter of 2014. Moreover, the Company, along with its Scientific Advisors, believes that it is essential to understand the outcome of a pending approval decision for a competitive female sexual dysfunction product by the FDA prior to finalizing the Femprox(r) clinical development program and initiating any potential partnering activities. Therefore, the Company plans to provide an update in early 2014 following its analysis of these two critical items.

Financial Status

Cash and cash equivalents totaled $20.6 million as of September 30, 2013, compared to $15.1 million as of December 31, 2012. Based upon our current business plan, the Company believes it has sufficient cash reserves to fund its ongoing operations through 2014. The Company filed its third quarter 2013 financial results with the U.S. Securities and Exchange Commission on November 12, 2013.

WHOOP! I SAY WHOOP! VITAROS!

This help! -- Room Temperature Device and Other Manufacturing Initiatives Progressing. Apricus continues to make progress with its next-generation, room temperature version of Vitaros. This new version is expected to have a targeted shelf life of at least 24 months and will not require refrigeration. The Company has contracted with an additional manufacturing partner that will serve as a second source of global supply for Vitaros. The Company expects this second manufacturing site, located in Canada, will be ready to supply cold chain Vitaros product to its commercialization partners in the second half of 2014. The site will also serve as the primary manufacturing site for the ongoing room temperature Vitarosdevelopment program. Apricus believes this next-generation, room temperature version will be a key driver of Vitarosmarket growth and expansion in 2015 http://pennyomega.com/img/apri.jpg

SAN DIEGO, May 25, 2012 (CRWENewswire) — Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Canadian Intellectual Property Office issued a Notice of Allowance for a Canadian patent on certain methods of manufacture for the Company’s platform NexACT(R) drug delivery technology.

Specifically, the patent covers the synthesis of Dodecyl 2-(N, N-Dimethylamino)-Propionate (DDAIP) by a transesterification chemical process. DDAIP opens up the tight junctions between cells, allowing drugs to be delivered to the bloodstream.

The patent application (No. 2,706,680), entitled “Crystalline Salts of Dodecyl 2-(N, N-Dimethylamino)-Propionate, is a divisional application of the already issued Canadian Patent No. 2,338,139 bearing the same title and covering crystal salts of DDAIP. When issued, this patent will protect this method of manufacture of DDAIP in Canada, and provides patent exclusivity to May 2020.

The transesterification approach to synthesizing DDAIP represents an advance in the manufacturing process of this technology. The resulting product contains relatively lower levels of by-products and unreacted reactants, which are undesirable and difficult to remove by conventional methods. The Company expects this method to bring significant cost savings for the finished product. This will be the 17th patent granted for this technology worldwide, with two applications pending in this patent family.

In addition, the New Zealand Intellectual Property Office issued a Notice of Acceptance for New Zealand patent application number 576,242, entitled “Stabilized Prostaglandin E Composition,” which claims formulations of Vitaros(R), Apricus Bio’s lead product candidate for the treatment of erectile dysfunction. When issued, this patent will grant exclusive rights to certain pharmaceutical compositions of Vitaros(R)–including its room temperature formulation in New Zealand. It will provide patent exclusivity until October 2027.

“These new patent allowances serve to further strengthen our global intellectual property positions,” said Bassam Damaj, President and Chief Executive Officer of Apricus Bio. “We continue to pursue an aggressive patent strategy that we believe will protect the DDAIP compound and method of manufacture including those relating to our more advanced room temperature formulations, and we will meaningfully expand the market exclusivity of our products in important territories.”

Apricus Bio currently owns approximately 144 issued patents and 143 patent applications, including eight allowed patent applications, on its NexACT(R) technology, its acquired products, and on other products and technologies throughout the world. Patents covering Vitaros(R), for erectile dysfunction, have been issued in Australia, Canada, Eurasia, Europe, Hong Kong, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Turkey, Taiwan, and the United States.
and beyond.

--------------------------------

Welcome from Yahoo board.Your questions if valid will be answered with facts.Smart guys on this board.

Great candlestick reliability high.
Outside Up Timeframe: 30 Minutes

Reliability: High

A reversal pattern.

This pattern is a more reliable addition to the standard Engulfing pattern. A bullish Engulfing pattern occurs in the first two candles. The third candlestick is confirmation of the bullish trend reversal.

Recognized Bearish Chart Patterns




Doji Star Bearish Timeframe: 15 Minutes, 30 Minutes, Hourly

Reliability: Moderate

A reversal pattern.

During an uptrend, the market builds strength on a long white candlestick and gaps up on the second candlestick. However, the second candlestick trades within a small range and closes at or near its open. This scenario generally shows erosion of confidence in the current trend. Confirmation of a

Is the tide changing for the better? http://www.investing.com/equities/apricus-biosciences-technical

Expanded article.Couple extra paragraphs. SAN DIEGO, Dec. 16, 2013 (GLOBE NEWSWIRE)

SAN DIEGO, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), announced today that it has expanded its exclusive license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies ("Sandoz"), for the commercialization of Vitaros®, indicated for the treatment of patients with erectile dysfunction ("ED"). In addition to the in-place collaboration in Germany, this expanded agreement now includes Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden and Switzerland (the "Expanded Territory").

In combination with the previously signed license agreement for Germany, Apricus is now eligible to receive up to approximately $63 million from Sandoz in upfront, regulatory, launch and sales milestone payments for Vitaros® in Germany and the Expanded Territory, which includes up to $4.5 million in new upfront and launch milestone compensation for the Expanded Territory.

"This expanded commercialization agreement with Sandoz accomplishes one of our key corporate objectives – the expansion of an existing Vitaros® partnership in Europe," said Richard Pascoe, Chief Executive Officer of Apricus. "We are pleased with the strong working relationship we have with Sandoz and we look forward to supporting their team as they bring this novel, topical, on-demand ED treatment option to physicians and patients throughout Northern Europe."

Vitaros® was approved in Europe under the Decentralized Procedure ("DCP") in June 2013. Since then, the product has received six national phase approvals in Europe, including Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom. Apricus continues to work independently, as well as with its license partners, to obtain country-by-country national phase approvals in the remaining CMS territories, including France, Spain, Belgium and Luxembourg. The Company's regulatory efforts, along with actions taken by its existing European license partners, are on track to obtain the remaining four European approvals during the fourth quarter of 2013 and the first quarter of 2014.

Vitaros® is currently licensed to Takeda in the United Kingdom, Sandoz in Germany, Austria, Benelux and the Nordics, Bracco in Italy, Laboratoires Majorelle in France, Monaco and certain Africa countries, and Abbott in Canada.

I used it in response to (reflections) question and comment like it says on the post.Like it says under RE- Reflection . No posting old storys rule now? If you do not think it is pertinent you should just say so. It was nothing more than that sir.

Join
Sign In












Help






Analyst Blog »


Zacks Equity Research
Apricus' Vitaros Approved in Europe

by Zacks Equity Research Published on June 11, 2013 | No Comments

APRI LLY JAZZ
.







Share


Print
.








Apricus Biosciences, Inc. (APRI - Snapshot Report) recently announced that its erectile dysfunction (ED) drug, Vitaros, has been approved under the European Decentralized Procedure (DCP).

Apricus, along with its commercialization partners, Sandoz, Takeda Pharmaceutical and Bracco, will now look to obtain national phase approvals to make Vitaros available in all territories across Europe.

Results from a phase III study evaluating the safety and efficacy of Vitaros and its long-term use in men who did not respond to phosphodiesterase type 5 (PDE-5) inhibitors like Viagra (n=325) showed that multiple doses of Vitaros (200 mcg and 300 mcg) improved erections in patients.

Apricus’ marketing approval application for Vitaros designated Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium and Luxembourg) who participated in the procedure.

Although Apricus believes that Vitaros has the potential to capture a good share of the PDE-5 inhibitor market (worth approximately $1 billion) once launched, we note that the market currently has big companies like Eli Lilly and Company (LLY - Analyst Report).

The company also mentioned that it will continue to seek additional partnership agreements for Vitaros in the rest of the European and global markets.

Apricus was recently engaged in a $17.1 million financing. It also divested multiple non-core assets and has also streamlined its global operations. This should allow the company to focus on its lead assets for male and female sexual health, namely, Vitaros and Femprox.

Apricus presently carries a Zacks Rank #4 (Sell). Currently, companies like Jazz Pharmaceuticals (JAZZ - Snapshot Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Just in case any spin info from somewhere else makes it to this board.I cannot find any GROUPS who have filed a complaint against Apricus.




No Complaints Found for: apricus

There have been no complaints filed through our agency against the business indicated above. If you feel this is in error, check your spelling and try again.

Complaints that list incomplete or inaccurate company contact information may not appear in our database if the information provided is insufficient to identify the organization in question.

Thanks good post.

Imo it looks like steady accumulation going on.Nice if this candlestick is correct.
APRI Candlestick Patterns









Candlestick Chart
Area Chart
5
15
30
1H
5H
1D
1W
1M
Show/Hide News

Interactive Chart





Apricus Biosciences Inc 1.750 -0.010 (-0.57%)


Dec 10Dec 11Dec 12Dec 131.6501.7001.7501.8001.8501.9001.750







Last update: 2013-12-13 10:14:00

Recognized Bullish Chart Patterns




Bullish doji Star Timeframe: Hourly

Reliability: Moderate

A reversal pattern.

During a downtrend, the market strengthens the bears with a long black candlestick and gaps open on the second one. However, the second candlestick trades within a small range and closes at or near its open. This scenario generally shows the potential for a rally, as many positions have been changed. Confirmation of the trend reversal would be a higher open on the next candlestick.

Recognized Bearish Chart Patterns



No Patterns were recognized.

Also from Aug 2013 .
kingme123 Friday, 08/23/13 09:30:50 AM
Re: kingme123 post# 9149



Post # of 11752






This Cantor Fitzgerald? LOL! http://www.reviewjournal.com/news/crime-courts/lawsuit-accuses-cantor-fitzgerald-taking-technology-benefit-las-vegas-subsidiary

I am a buyer.I say thank you for the gift. CHECK THE VOLUME.
How it works

This process can be used by hedge funds to either pump up a stock or to trash a stock but since I am using Herbalife as an example, we will discuss that situation. First information is widely distributed to make investors wonder about the company and to put fear into those longs that hold the stock. Next, high volume shorting takes place to drive the company's share price down.

As the short attack continues, more people parade out news to continue to put questions in the back of investors' minds. On a daily basis, shorts use computerized trading to control the direction of the share price. At opportune times, the shorts overwhelm the buyers (bid price) of the stock by selling short large number of shares to drive the share price down and to eliminate the buyers for the stock at that given time. For people who are not familiar with the bid/ask process of trading stocks, here is a link to explain that process.

Here is the reply you received in Aug when you brought this up the first time.Your post was on 08/05/13
value1008 Member Level Monday, 08/05/13 10:52:28 PM
Re: PZLazlo post# 8671



Post # of 11744






Here's from an independent urologists' publication:


http://urologytimes.modernmedicine.com/node/371953
"The leading news source for urologists"

Urology Product Preview
July 29, 2013

ED agent shows efficacy in men unresponsive to PDE-5 inhibitors

Phase III data for Vitaros, a product candidate for the treatment of erectile dysfunction, were presented at the AUA annual meeting in San Diego. The analysis evaluated the safety and efficacy of Vitaros after 12 weeks, and longer term use, in men previously unresponsive to phosphodiesterase type-5 inhibitors. Results showed that 200-mcg and 300-mcg doses of Vitaros improved erections in this population, and adverse events were mild to moderate, similar to those seen in the control group, and decreased with repeated exposure, according to Apricus Biosciences, which is developing the drug.

Mr. D. back up chart. http://www.shortanalytics.com/getshortchart.php?tsymbol=APRI

Another easy one. In an organization with voting members, e.g., a professional society, the board acts on behalf of, and is subordinate to, the organization's full group, which usually chooses the members of the board. In a stock corporation, the board is elected by the shareholders and is the highest authority in the management of the corporation. In a non-stock corporation with no general voting membership

Check this out Starbuck2 http://seekingalpha.com/instablog/2918951-g-hudson/1026551-how-the-big-players-manipulate-the-stock-market

http://www.bioportfolio.com/news/article/1751589/Apricus-Elects-Kleanthis-G-Xanthopoulos-Ph-D-as-New-Chairman.html

Check it out. :)http://www.investing.com/equities/apricus-biosciences-candlestick

Towards the bottom of page 1 Billion.http://buyalprostadilcream.com/vitaros-cream-alprostadil-cream-approval-in-europe/

Huge Potential But Tough Entry: Female Sexual Dysfunction Drugs
By Bio-Wire | Stock Markets | May 07, 2013 11:51AM GMT | Add a Comment


Bio-Wire Bio-Wire
Articles (179)

My Homepage


Article













Female Sexual Dysfunction (FSD) is often overshadowed by the more prominent erectile dysfunction market. While companies like Pfizer (PFE) recruit the likes of Bob Dole and other prominent celebrities to help push Viagra, the attention on FSD has been lacking to say the least. This obscures an analysis of a National Health and Social Life Survey performed six years before initial FDA approval of Viagra which estimated that 43% of women suffer from symptoms of FSD. This and other studies imply that there is indeed a vast and significant unmet need for FSD treatments that needs to be addressed to improve the wellbeing of millions of women. In addition to this, there is a huge and untapped therapeutic market that offers a multi-billion opportunity (mimicking the size and scope of the Viagra/Cialis market) for drug developers and their investors.

Currently there is a transdermal testosterone product for FSD available that was developed by Watson Pharmaceuticals along with partner Procter & Gamble (PG) which is sold in Europe, although the drug never made it to FDA approval and had its NDA withdrawn in 2004 due to concerns over its safety data. Another big attempt by the US market by Boehringer Ingelheim Pharmaceuticals with the drug that was commonly referred to as “Pink Viagra” fell flat on its face in 2010 after the company failed to convince the FDA of the utility of the product. In more recent history, we saw the failure of the testosterone gel known as “Libigel” hurt shares of BioSante Pharmaceuticals (BPAX) at the end of 2011 after the placebo arm outperformed the Libigel arm in a Phase III study.

Despite all of the trouble that companies have had in the past in their attempts at the US FSD market, the unmet need (and monetary potential) remains up for the taking. Investors who are familiar with the space are now looking at other FSD drug developers have a shot at FDA approval.

One of the leading candidates in the space is Palatin (PTN), which anticipates the start of a Phase III trial later this year. The Company is testing bremelanotide, a peptide melanocortin receptor agonist, in patients with FSD. Bremalanotide works via activation of melanocortin receptors in the central nervous system, and is intended for on-demand use approximately an hour prior to anticipated sexual activity. In the first quarter of 2013, Palatin released top-line data for their Phase IIb, at-home clinical trial in patients with female sexual dysfunction. The trial was a randomized, double-blinded study testing the safety and efficacy of bremalanotide in almost 400 patients with FSD. The patients were separated into one of four trial groups and received bremalanotide at 0.75 mg, 1.25 mg, 1.75 mg, or placebo. Patients self-administered via a single sub-cutaneous dose prior to an anticipated sexual encounter.

The trial hit on the primary and key secondary endpoints, a major success, demonstrating a good safety profile for bremalanotide and statistically significant increases in the number of Satisfying Sexual Events (SSE) versus placebo. The most common adverse reactions with incidence over 5% among bremalanotide users at any dose included nausea, flushing, and headache. The FDA approved a Phase III trial design with bremalanotide, and the Company could start the trial as early as Q4 2013.

Palatin is in good financial shape with $32.9 million in cash at the end 2012. With a cash burn rate of approximately $12 million per year, the company can readily fund its operations through FY2014, including the upcoming Phase III trial. With a market capitalization of about $24 million, shares of Palatin are actually trading below the value of cash on hand, so this may be a very attractive entry point for investors who want exposure to a potentially successful FSD drug development program.

Also promising for Palatin is the notion that there are no strong competitors in the FSD space. As mentioned earlier, BioSante Pharmaceuticals (BPAX) announced very poor results from two Phase III trials with their candidate LibiGel in 2011. These trials did not achieve statistical significance, forcing the company to temporarily step back from the program. While the company has not officially abandoned the Libigel program, it’s difficult to see how they will overcome the problem of the extremely high placebo response.

Palatin’s program is differentiated from BioSante’s failed effort because bremalanotide uses a specific MOA directly affecting FSD, while BioSante is simply making another testosterone gel.

Apricus (APRI) is the only company that is close to an approved treatment and has finished a Phase III study with their candidate Femprox (alprostadil and DDAIP HCl). The company is planning to submit an application for approval in Canada in the near future.

The Takeaway
Female Sexual Dysfunction is a huge unmet need in the United States, although the companies that have made attempts on this drug indication in the past have been unsuccessful. Currently, there are only a handful of companies with drug development plans that target this indication. Some are better than others. BioSante’s Libigel, which is just another testosterone gel, doesn’t look as likely to succeed while Palatin’s melanocortin receptor agonist bremalanotide and also Apricus’ topical prostaglandin agonist Femprox look more interesting.

I bought more at $1.84 I am still an APRI believer.

Cool APRI chart. http://stockcharts.com/h-sc/ui?s=APRI&p=D&yr=0&mn=6&dy=0&id=p35094524034&a=324912428&listNum=2

Thanks eicoman ,the blocks will fall in place soon imo.